| Year |
Citation |
Score |
| 2020 |
Chen KG, Duran GE, Mogul MJ, Wang YC, Ross KL, Jaffrézou JP, Huff LM, Johnson KR, Fojo T, Lacayo NJ, Sikic BI. Genomic stability at the coding regions of the multidrug transporter gene : insights into the development of alternative drug resistance mechanisms in human leukemia cells. Cancer Drug Resistance (Alhambra, Calif.). 3: 959-979. PMID 34541464 DOI: 10.20517/cdr.2020.51 |
0.728 |
|
| 2020 |
Karol SE, Cooper TM, Mead PE, Crews KR, Panetta JC, Alexander TB, Taub JW, Lacayo NJ, Heym KM, Kuo DJ, Schiff DE, Bhojwani D, Ge Y, Klco JM, Ribeiro RC, et al. Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer. PMID 32809242 DOI: 10.1002/Cncr.33156 |
0.383 |
|
| 2020 |
Chae HD, Dutta R, Tiu B, Hoff FW, Accordi B, Serafin V, Youn M, Huang M, Sumarsono N, Davis KL, Lacayo NJ, Pigazzi M, Horton TM, Kornblau SM, Sakamoto KM. RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget. 11: 2387-2403. PMID 32637030 DOI: 10.18632/Oncotarget.27630 |
0.367 |
|
| 2020 |
Wojcicki AV, Kasowski MM, Sakamoto KM, Lacayo N. Metabolomics in acute myeloid leukemia. Molecular Genetics and Metabolism. PMID 32457018 DOI: 10.1016/J.Ymgme.2020.05.005 |
0.398 |
|
| 2020 |
Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, Wolf J, Klco JM, Mead PE, Das Gupta S, Kim SY, Salem AH, Palenski T, Lacayo NJ, Pui CH, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. The Lancet. Oncology. PMID 32171069 DOI: 10.1016/S1470-2045(20)30060-7 |
0.401 |
|
| 2020 |
Wojcicki AV, Kadapakkam M, Frymoyer A, Lacayo N, Chae HD, Sakamoto KM. Repurposing Drugs for Acute Myeloid Leukemia: A Worthy Cause or a Futile Pursuit? Cancers. 12. PMID 32069925 DOI: 10.3390/Cancers12020441 |
0.391 |
|
| 2020 |
Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, Larrier N, Maese L, Mahadeo K, Nanda R, Nardi V, et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 81-112. PMID 31910389 DOI: 10.6004/Jnccn.2020.0001 |
0.351 |
|
| 2020 |
Huang M, Zeki J, Sumarsono N, Coles GL, Taylor JS, Danzer E, Bruzoni M, Hazard FK, Lacayo NJ, Sakamoto KM, Dunn JCY, Spunt SL, Chiu B. EPIGENETIC TARGETING OF TERT-ASSOCIATED GENE EXPRESSION SIGNATURE IN HUMAN NEUROBLASTOMA WITH TERT OVEREXPRESSION. Cancer Research. PMID 31900258 DOI: 10.1158/0008-5472.Can-19-2560 |
0.4 |
|
| 2020 |
Sanders LM, Lyle AG, Beale HC, Kephart ET, Learned K, Peralez J, Lacayo N, Rangaswami A, Spunt SL, Bjork I, Haussler D, Salama SR, Vaske OM. Abstract A44: Comparative gene expression analysis for identification and prioritization of therapeutic targets in a cohort of childhood cancers Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A44 |
0.382 |
|
| 2019 |
Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Yeoh AE, Coustan-Smith E, Wang L, Triplett B, Raimondi SC, Klco J, et al. Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900327. PMID 31246522 DOI: 10.1200/Jco.19.00327 |
0.382 |
|
| 2019 |
Nguyen R, Wu H, Pounds S, Inaba H, Ribeiro RC, Cullins D, Rooney B, Bell T, Lacayo NJ, Heym K, Degar B, Schiff D, Janssen WE, Triplett B, Pui CH, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. Journal For Immunotherapy of Cancer. 7: 81. PMID 30894213 DOI: 10.1186/S40425-019-0564-6 |
0.388 |
|
| 2019 |
Karol SE, Alexander T, Das Gupta S, Pounds SB, Canavera K, Klco JM, Lacayo NJ, Pui C, Opferman JT, Rubnitz JE. Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia. Journal of Clinical Oncology. 37: 10004-10004. DOI: 10.1200/Jco.2019.37.15_Suppl.10004 |
0.361 |
|
| 2019 |
Zhang C, Sharma R, Satbir T, Cheney A, Vaske O, Sanders L, Boklan J, Lewis VA, Anderson R, Kovalchuk O, Lacayo NJ, Narendran A, Bielamowicz KJ. Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia Blood. 134: 2633-2633. DOI: 10.1182/Blood-2019-131444 |
0.429 |
|
| 2019 |
Karol SE, Alexander T, Budraja A, Pounds S, Canavera KE, Wang L, Wolf J, Klco JM, Salem AH, Palenski T, Lacayo NJ, Pui C, Opferman JT, Rubnitz J. Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia Blood. 134: 178-178. DOI: 10.1182/Blood-2019-127716 |
0.399 |
|
| 2019 |
Lacayo NJ, Pullarkat VA, Stock W, Jabbour E, Bajel A, Rubnitz J, Leonard J, Mullighan CG, Khaw SL, Vear SI, Opferman JT, Salem AH, Schmidt M, Tong B, Zhou L, et al. Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Blood. 134: 285-285. DOI: 10.1182/Blood-2019-126977 |
0.318 |
|
| 2019 |
Shah AT, Breese MR, Lee AG, Martell HJ, Tanasa B, Leung SG, Spillingeer A, Liu H, Behroozfard I, Dinh P, Hazard FK, Cho S, Rangaswami A, Lacayo NJ, Spunt SL, et al. Abstract 3665: Integrative analysis of whole-genome and RNA sequencing in high-risk pediatric malignancies Cancer Research. 80: 3665-3665. DOI: 10.1158/1538-7445.Pedca19-B20 |
0.419 |
|
| 2019 |
Jabbour E, Mullighan CG, Pullarkat VA, Lacayo NJ, Bajel A, Rubnitz J, Leonard J, Khaw SL, Vear SI, Alexander T, Norris R, Salem A, Schmidt M, Tong B, Zhou Y, et al. Combination BCL-2 Inhibitor Therapy with Venetoclax and Navitoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Clinical Lymphoma Myeloma and Leukemia. 19: S184-S185. DOI: 10.1016/J.Clml.2019.07.022 |
0.396 |
|
| 2018 |
Theruvath AJ, Nejadnik H, Muehe AM, Gassert F, Lacayo NJ, Goodman SB, Daldrup-Link HE. Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof of Concept Study in Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30224340 DOI: 10.1158/1078-0432.Ccr-18-1687 |
0.302 |
|
| 2018 |
Good Z, Sarno J, Jager A, Samusik N, Aghaeepour N, Simonds EF, White L, Lacayo NJ, Fantl WJ, Fazio G, Gaipa G, Biondi A, Tibshirani R, Bendall SC, Nolan GP, et al. Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. Nature Medicine. PMID 29505032 DOI: 10.1016/J.Exphem.2018.06.027 |
0.364 |
|
| 2018 |
Chae HD, Cox N, Dahl GV, Lacayo NJ, Davis KL, Capolicchio S, Smith M, Sakamoto KM. Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget. 9: 4301-4317. PMID 29435104 DOI: 10.18632/Oncotarget.23794 |
0.409 |
|
| 2018 |
Alexander T, Khaw SL, Rubnitz JE, Vear SI, Lacayo NJ, Schmidt M, Tong B, Rosenwinkel L, Bensman L, Verdugo M, Kim SY, Jabbour E, Stock W. Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia. Journal of Clinical Oncology. 36: TPS10575-TPS10575. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps10575 |
0.414 |
|
| 2018 |
Chae H, Murphy LC, Donato M, Lee AG, Sweet-Cordero EA, Abidi P, Bittencourt H, Lacayo NJ, Dahl GVH, Aftandilian C, Davis KL, Huang M, Sumarsono N, Redell M, Fu CH, et al. Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells Blood. 132: 4246-4246. DOI: 10.1182/Blood-2018-99-119974 |
0.424 |
|
| 2018 |
Alexander T, Lacayo NJ, Pullarkat VA, Jabbour EJ, Khaw SL, Mullighan CG, Bajel A, Leonard J, Norris R, Rubnitz J, Vear SI, Schmidt M, Tong B, Zhou Y, Ross JA, et al. Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Blood. 132: 3966-3966. DOI: 10.1182/Blood-2018-99-113464 |
0.369 |
|
| 2018 |
Aftandilian C, Sakamoto KM, Davis KL, Dahl GVH, Lacayo NJ. Chromatin Remodeling Therapy and Capizzi Methotrexate in Treatment-Related MDS/AML Blood. 132: 5222-5222. DOI: 10.1182/Blood-2018-99-110481 |
0.376 |
|
| 2018 |
Hantel A, Wynne J, Lacayo N, Khaw SL, Rubnitz J, Mullighan C, Schmidt M, Zhou Y, Ross JA, Rosenwinkel L, Kim SY, Jabbour E, Alexander T. Safety and Efficacy of the BCL Inhibitors Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Clinical Lymphoma Myeloma and Leukemia. 18: S184-S185. DOI: 10.1016/J.Clml.2018.07.016 |
0.369 |
|
| 2017 |
Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. PMID 28389462 DOI: 10.1182/Blood-2017-01-764324 |
0.419 |
|
| 2016 |
Alexander TB, Lacayo NJ, Choi JK, Ribeiro RC, Pui CH, Rubnitz JE. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27507877 DOI: 10.1200/Jco.2016.67.5066 |
0.376 |
|
| 2016 |
Mitton B, Chae HD, Hsu K, Dutta R, Aldana-Masangkay G, Ferrari R, Davis K, Tiu BC, Kaul A, Lacayo N, Dahl G, Xie F, Li BX, Breese MR, Landaw EM, et al. Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells. Leukemia. PMID 27211267 DOI: 10.1038/Leu.2016.139 |
0.402 |
|
| 2015 |
Chae HD, Mitton B, Lacayo NJ, Sakamoto KM. Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA. Leukemia. 29: 1379-89. PMID 25541153 DOI: 10.1038/Leu.2014.350 |
0.348 |
|
| 2014 |
Kesler SR, Gugel M, Pritchard-Berman M, Lee C, Kutner E, Hosseini SM, Dahl G, Lacayo N. Altered resting state functional connectivity in young survivors of acute lymphoblastic leukemia. Pediatric Blood & Cancer. 61: 1295-9. PMID 24619953 DOI: 10.1002/Pbc.25022 |
0.306 |
|
| 2014 |
Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head DR, Raimondi SC, Hirsch BA, Gerbing RB, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS. Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children’s Oncology Group (COG) Phase III AAML0431 Trial Blood. 124: 278-278. DOI: 10.1182/Blood.V124.21.278.278 |
0.429 |
|
| 2013 |
Lacayo NJ, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC, Cesano A, Gerbing R, Ravindranath Y, Dahl GV, Gamis A, et al. Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group. British Journal of Haematology. 162: 250-62. PMID 23682827 DOI: 10.1111/Bjh.12370 |
0.4 |
|
| 2013 |
Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE, Cesano A, Walter RB. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. Plos One. 8: e53518. PMID 23320091 DOI: 10.1371/Journal.Pone.0053518 |
0.397 |
|
| 2013 |
O'Brien MM, Cao X, Pounds S, Dahl GV, Raimondi SC, Lacayo NJ, Taub J, Chang M, Weinstein HJ, Ravindranath Y, Inaba H, Campana D, Pui CH, Rubnitz JE. Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421. Leukemia. 27: 731-4. PMID 22918081 DOI: 10.1038/Leu.2012.223 |
0.334 |
|
| 2013 |
Lacayo NJ, Weng L, Gawad C, Faham M, Dahl GV. Use Of Rearranged Immune Receptor Sequencing To Measure Minimal Residual Disease (MRD) In Bone Marrow, Cerebrospinal Fluid and Testes In Relapsed Childhood Acute Lymphoblastic Leukemia Blood. 122: 4984-4984. DOI: 10.1182/Blood.V122.21.4984.4984 |
0.401 |
|
| 2013 |
Breese E, Agarwal R, Kharbanda S, Breese M, Amylon M, Weinberg KI, Porteus M, Dahl G, Lacayo N, Schlis K, Willert JR. Single Institution Experience With Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and AYA Patients With Acute Leukemia Biology of Blood and Marrow Transplantation. 19: S242-S243. DOI: 10.1016/J.Bbmt.2012.11.313 |
0.329 |
|
| 2012 |
Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB, Faham M, Dahl G, Lacayo N. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood. 120: 4407-17. PMID 22932801 DOI: 10.1182/Blood-2012-05-429811 |
0.34 |
|
| 2012 |
Rosen DB, Cordeiro JA, Cohen A, Lacayo N, Hogge D, Hawtin RE, Cesano A. Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leukemia Research. 36: 900-4. PMID 22521550 DOI: 10.1016/J.Leukres.2012.02.022 |
0.397 |
|
| 2012 |
Gawad C, Borowitz MJ, Dahl GV, Devidas M, Faham M, Moorhead M, Wood BL, Zheng J, Loh ML, Lacayo NJ. Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort Blood. 120: 1440-1440. DOI: 10.1182/Blood.V120.21.1440.1440 |
0.398 |
|
| 2011 |
Lacayo NJ, Alonzo TA, Gayko U, Westfall M, Purvis N, Putta S, Hackett J, Cohen AC, Gerbing RB, Dahl GV, Gamis AS, Meshinchi S. Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results, Blood. 118: 3544-3544. DOI: 10.1182/Blood.V118.21.3544.3544 |
0.429 |
|
| 2011 |
Gawad C, Faham M, Willis T, Moorhead M, Carlton V, Zheng J, Klinger M, Dahl GV, Lacayo NJ. Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region in Diagnostic Samples of Pediatric Acute Lymphoblastic Leukemia Identifies Hundreds of Clonal Subpopulations with Multiple Immunophenotypes Blood. 118: 1436-1436. DOI: 10.1182/Blood.V118.21.1436.1436 |
0.37 |
|
| 2011 |
Rosen DB, Cordeiro J, Cohen AC, Lacayo N, Hogge D, Cesano A, Hawtin RE. Abstract B72: Assessing specific biological mechanisms of drug resistance in adult and pediatric AML. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B72 |
0.39 |
|
| 2010 |
Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. The Lancet. Oncology. 11: 543-52. PMID 20451454 DOI: 10.1182/Blood.V114.22.16.16 |
0.375 |
|
| 2010 |
O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the children's oncology group Pediatric Blood and Cancer. 54: 694-702. PMID 20209646 DOI: 10.1002/Pbc.22366 |
0.585 |
|
| 2010 |
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 115: 2372-9. PMID 20056794 DOI: 10.1182/Blood-2009-09-241075 |
0.384 |
|
| 2010 |
Sikic BI, Tibshirani R, Lacayo NJ. Reply to D.R. Catchpoole et al Journal of Clinical Oncology. 28: e725. DOI: 10.1200/Jco.2010.32.0283 |
0.547 |
|
| 2010 |
Lacayo NJ, Cohen A, Westfall M, Lackey A, Xin X(, Gayko U, Putta S, Meshinchi S, Raimondi SC, Alonzo TA, Arceci RJ, Ravindranath Y, Dahl GVH, Cesano A. Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421 Blood. 116: 954-954. DOI: 10.1182/Blood.V116.21.954.954 |
0.414 |
|
| 2010 |
Cesano A, Gotlib JR, Lacayo NJ, Putta S, Lackey A, Gayko U, Kornblau SM. Sample Cryopreservation Does Not Affect Functional Read Outs In SCNP Assays: Implications for Biomarker Development Blood. 116: 4843-4843. DOI: 10.1182/Blood.V116.21.4843.4843 |
0.381 |
|
| 2009 |
Noronha SA, Farrar JE, Alonzo TA, Gerbing RB, Lacayo NJ, Dahl GV, Ravindranath Y, Arceci RJ, Loeb DM. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 53: 1136-9. PMID 19618455 DOI: 10.1002/Pbc.22142 |
0.405 |
|
| 2009 |
Schiffman JD, Wang Y, McPherson LA, Welch K, Zhang N, Davis R, Lacayo NJ, Dahl GV, Faham M, Ford JM, Ji HP. Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. Cancer Genetics and Cytogenetics. 193: 9-18. PMID 19602459 DOI: 10.1016/J.Cancergencyto.2009.03.005 |
0.441 |
|
| 2009 |
O'Brien M, Dahl G, Pounds S, Lacayo NJ, Taub J, Chang M, Weinstein HJ, Ravindranath Y, Campana D, Pui C, Rubnitz J. Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome. Blood. 114: 482-482. DOI: 10.1182/Blood.V114.22.482.482 |
0.398 |
|
| 2008 |
Sikic BI, Tibshirani R, Lacayo NJ. Genomics of childhood leukemias: the virtue of complexity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4367-8. PMID 18802145 DOI: 10.1200/Jco.2008.16.4285 |
0.597 |
|
| 2008 |
Hazard FK, Zhao S, Schiffman JD, Lacayo NJ, Dahl GV, Natkunam Y. Tissue microarrays from bone marrow aspirates for high-throughput assessment of immunohistologic markers in pediatric acute leukemia. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 11: 283-90. PMID 17990919 DOI: 10.2350/07-04-0253.1 |
0.41 |
|
| 2007 |
Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D. The incidence and clinical significance of nucleophosmin mutations in childhood AML Blood. 110: 979-985. PMID 17440048 DOI: 10.1182/Blood-2007-02-076604 |
0.415 |
|
| 2007 |
Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, Sikic BI. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1341-9. PMID 17312329 DOI: 10.1200/JCO.2006.09.3534 |
0.568 |
|
| 2007 |
Schiffman JD, Welch KM, Davis R, Dahl GV, Lacayo NJ, Faham M, Ford JM, Ji H. Adapting molecular inversion probe (MIP) technology for allele quantification in childhood leukemia Journal of Clinical Oncology. 25: 9530-9530. DOI: 10.1200/Jco.2007.25.18_Suppl.9530 |
0.426 |
|
| 2007 |
Schiffman JD, Welch K, Davis R, Lacayo NJ, Dahl GV, Wang Y, Faham M, Ford JM, Ji HP. Molecular Inversion Probes (MIPs) Identify Novel Areas of Allelic Imbalance in Childhood Leukemia. Blood. 110: 1438-1438. DOI: 10.1182/Blood.V110.11.1438.1438 |
0.428 |
|
| 2006 |
Lacayo NJ, DiMartino JF, Wei MC, Dahl GV. CpG island methylator phenotype and childhood leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4787-9. PMID 16914562 DOI: 10.1158/1078-0432.Ccr-06-0651 |
0.35 |
|
| 2006 |
DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 20: 426-32. PMID 16424866 DOI: 10.1038/Sj.Leu.2404102 |
0.584 |
|
| 2006 |
Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 107: 1315-24. PMID 16254147 DOI: 10.1182/Blood-2004-08-3218 |
0.578 |
|
| 2006 |
Schiffman JD, Ji H, Welch KM, Davis R, Van Houten Dahl G, Lacayo NJ, Ford JM. Novel Allele Quantification Method To Classify Childhood Leukemia. Blood. 108: 2273-2273. DOI: 10.1182/Blood.V108.11.2273.2273 |
0.396 |
|
| 2006 |
Brown P, McIntyre E, Rau R, Alonzo TA, Gerbing R, Meshinchi S, Lacayo N, Chang M, Arceci R, Small D. Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study. Blood. 108: 221-221. DOI: 10.1182/Blood.V108.11.221.221 |
0.421 |
|
| 2006 |
Lacayo NJ, O’Brien M, Jain S, Meshinchi S, Yu R, Juric D, Chang MN, Tibshirani R, Ravindranath Y, Weinstein HJ, Sikic BI, Van Houten Dahl G. Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. Blood. 108: 1915-1915. DOI: 10.1182/Blood.V108.11.1915.1915 |
0.594 |
|
| 2005 |
Kuo DJ, Lacayo NJ, Hoang D, Juric D, Raimondi SC, Chen D, Chang MN, Ravindranath Y, Weinstein HJ, Sikic BI, Dahl GVH. Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421. Blood. 106: 2771-2771. DOI: 10.1182/Blood.V106.11.2771.2771 |
0.576 |
|
| 2005 |
Rubnitz J, Razzouk B, Bowman P, Dahl G, Lacayo N, Taub J, Ravindranath Y, Meshinchi S, Airewele G, Lensing S, Pounds S, Ribeiro R, Pui C, Coustan-Smith E, Campana D. Improved Remission Induction Rate of Childhood AML: Preliminary Results of the AML02 Trial. Blood. 106: 275-275. DOI: 10.1182/Blood.V106.11.275.275 |
0.402 |
|
| 2005 |
Lacayo N, Meshinchi S, Raimondi S, Saraiya C, O’Brien M, Yu R, Juric D, Chang M, Willman C, Tibshirani R, Ravindranath Y, Sikic B, Weinstein H, Dahl GVH. Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. Blood. 106: 2372-2372. DOI: 10.1182/Blood.V106.11.2372.2372 |
0.609 |
|
| 2004 |
Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood. 104: 2646-54. PMID 15251987 DOI: 10.1182/Blood-2003-12-4449 |
0.611 |
|
| 2004 |
Lacayo NJ, Meshinchi S, Raimondi SC, Kuo DJ, Yu R, Chang MN, Willman CL, Tibshirani R, Ravindranath Y, Sikic BI, Weinstein H, Dahl GV. FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421. Blood. 104: 570-570. DOI: 10.1182/Blood.V104.11.570.570 |
0.61 |
|
| 2004 |
Kuo DJ, Lacayo NJ, Buck S, Yu R, Saraiya C, Douglas L, Weinstein H, Chang M, Willman CL, Tibshirani R, Dahl GV, Sikic B, Ravindranath Y. Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421. Blood. 104: 1130-1130. DOI: 10.1182/Blood.V104.11.1130.1130 |
0.628 |
|
| 2004 |
DiMartino JF, Lacayo NJ, Varadi M, Ravindranath Y, Yu R, Sikic B, Raimondi SC, Dahl GV. Osteonectin/SPARC Is Epigenetically Silenced in AML with MLL Gene Rearrangements and Selectively Inhibits the Growth of MLL Rearranged Cell Lines. Blood. 104: 1106-1106. DOI: 10.1182/Blood.V104.11.1106.1106 |
0.598 |
|
| 2003 |
Lacayo NJ, Duran GE, Sikic BI. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. Journal of Experimental Therapeutics & Oncology. 3: 127-35. PMID 14641819 DOI: 10.1046/J.1359-4117.2003.01088.X |
0.578 |
|
| 2002 |
Chen GK, Lacayo NJ, Durán GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, Sikic BI. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes, Chromosomes & Cancer. 34: 372-83. PMID 12112526 DOI: 10.1002/Gcc.10067 |
0.599 |
|
| 2002 |
Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, Bomgaars L, Lauer SJ, Sikic BI, Dahl GV. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia. 16: 920-7. PMID 11986955 DOI: 10.1038/Sj.Leu.2402455 |
0.564 |
|
| 2000 |
Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, Arceci RJ. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 1867-75. PMID 10784627 DOI: 10.1200/Jco.2000.18.9.1867 |
0.586 |
|
| 2000 |
Chen GK, Lacayo NJ, Durán GE, Cohen D, Sikic BI. Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335). Molecular Pharmacology. 57: 769-77. PMID 10727524 DOI: 10.1124/Mol.57.4.769 |
0.538 |
|
| 1997 |
Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou JP, Dumontet C, Sikic BI. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. The Journal of Biological Chemistry. 272: 5974-82. PMID 9038218 DOI: 10.1074/Jbc.272.9.5974 |
0.649 |
|
| Show low-probability matches. |